New drug combo shows promise for tough esophageal cancer
NCT ID NCT02962063
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests adding the immunotherapy drug durvalumab to standard chemoradiation for people with esophageal or gastroesophageal junction cancer. About 64 participants will receive the combination to see if it is safe and effective. The goal is to improve cancer control without increasing side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
durvalumab (a drug that helps the immune system fight cancer)
What this could lead to
If successful, this could lead to a more effective treatment for esophageal cancer by combining immunotherapy with standard chemoradiation.
What could go wrong
This is an early-phase trial with only 64 participants, so results may not apply broadly. There is a risk of serious side effects from the combination therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Commack
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Nassau
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering Rockville Centre
Rockville Centre, New York, 11570, United States
-
Memorial Sloan Kettering Westchester
Harrison, New York, 10604, United States